TY  - JOUR
AU  - Burchardt, Norah A
AU  - Eliassen, A Heather
AU  - Shafrir, Amy L
AU  - Rosner, Bernard
AU  - Tamimi, Rulla
AU  - Kaaks, Rudolf
AU  - Tworoger, Shelley S
AU  - Turzanski-Fortner, Renée
TI  - Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study.
JO  - American journal of obstetrics and gynecology
VL  - 226
IS  - 6
SN  - 0002-9378
CY  - St. Louis, Mo.
PB  - Mosby
M1  - DKFZ-2021-03188
SP  - 821.e1-821.e26
PY  - 2022
N1  - #EA:C020#LA:C020# / 2022 Jun;226(6):821.e1-821.e26
AB  - Oral contraceptive (OC) use has been associated with higher breast cancer risk; however, evidence on the associations between different OC formulations and breast cancer risk, especially by disease subtype, is limited.To evaluate associations between OC use by formulation and breast cancer risk by disease subtype.This prospective cohort study included 107,069 women from the Nurses' Health Study II with recalled OC use from age 13 to baseline (1989) and updated data on OC use until 2009 collected via biennial questionnaires. A total of 5,799 breast cancer cases were identified through 2017. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95
KW  - breast cancer (Other)
KW  - epidemiology (Other)
KW  - estrogen (Other)
KW  - hormonal contraception (Other)
KW  - molecular subtypes (Other)
KW  - oral contraception (Other)
KW  - progestin (Other)
KW  - risk factors (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34921803
DO  - DOI:10.1016/j.ajog.2021.12.022
UR  - https://inrepo02.dkfz.de/record/178190
ER  -